BioStem Technologies (BSEM)
Manufacturer of placental-tissue allografts for wound care and surgical applications.
$3.58
Pre-market+0.02 (+0.56%)
At close$3.56(+1.71%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 42 | 74 | 83 | 103 | 73 | 49 | 10 | −85 | 6 | 8 |
| Cost of revenue | 1 | 2 | 4 | 4 | 4 | 1 | 1 | 1 | 0 | 3 | 4 |
| Gross profit | 11 | 40 | 71 | 78 | 99 | 72 | 49 | 9 | −85 | 3 | 4 |
| 14 | 35 | 62 | 69 | 91 | 66 | 48 | 8 | −78 | 12 | 13 | |
| Research & development | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 1 |
| 13 | 35 | 62 | 68 | 90 | 65 | 46 | 6 | −79 | 11 | 12 | |
| Selling & marketing | 12 | 0 | 0 | 65 | 81 | 58 | 40 | 1 | 0 | 0 | 0 |
| General & administrative | 1 | 0 | 0 | 3 | 8 | 7 | 7 | 4 | 0 | 0 | 0 |
| Other expenses | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −3 | 5 | 9 | 9 | 8 | 5 | 0 | 1 | −8 | −9 | −8 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | 4 | 9 | 9 | 8 | 5 | 0 | 1 | −7 | −9 | −9 |
| Income tax expense | 0 | 1 | 2 | 2 | −7 | 1 | 1 | 1 | 4 | 0 | 0 |
| Net income from continuing operations | −3 | 3 | 6 | 7 | 16 | 4 | −1 | 1 | −11 | −9 | −9 |
| Net income | −3 | 3 | 6 | 7 | 16 | 4 | −1 | 1 | −11 | −9 | −9 |
| EPS, basic | −$0.18 | $0.20 | $0.39 | $0.42 | $0.89 | $0.27 | −$0.03 | $0.05 | −$0.67 | −$0.52 | −$0.52 |
| EPS, diluted | −$0.18 | $0.17 | $0.30 | $0.32 | $0.64 | $0.17 | −$0.02 | $0.03 | −$0.67 | −$0.52 | −$0.52 |
| Weighted average shares, basic | 15 | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 |
| Weighted average shares, diluted | 15 | 19 | 21 | 21 | 23 | 26 | 25 | 23 | 17 | 17 | 17 |
| EBITDA | −2 | 5 | 9 | 9 | 9 | 5 | 0 | 2 | −7 | −8 | −8 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| EBIT | −2 | 5 | 9 | 9 | 8 | 5 | 0 | 1 | −8 | −9 | −8 |